^(131)I治疗老年甲亢合并心脏疾病患者临床疗效分析  

Clinical Curative Effect Analysis of ^(131)I in Treating Senile Hyperthyroid Complications with Heart Diseases

作　　者：蒙艳 陈刚 Meng Yan;Chen Gang(Liuzhou Workers' Hospital, Guangxi Province, Liuzhou 545005, China)

机构地区：[1]柳州市工人医院内分泌科,柳州545005 [2]柳州市工人医院心内科,柳州545005

出　　处：《中国医药导刊》2016年第7期710-711,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:分析^(131)I与抗甲状腺药物(ATD)治疗老年甲亢合并心脏疾病患者的临床疗效。方法:老年甲亢合并心脏疾病患者276例分为^(131)I治疗组(146例)与ATD治疗组(130例),比较两组入院时年龄、性别、甲功水平、B型钠尿肽前体(NT-Pro BNP)、心室率、左室射血分数(LVEF)。观察两组治疗前后的甲功水平、血浆(NT-Pro BNP)、心室率、LVEF等指标。结果:两组入院时年龄、性别、甲功水平、NT-Pro BNP、心室率、LVEF无显著性差异(P>0.05)。治疗后3、6、12个月,ATD治疗组甲功水平、NTPro BNP、心室率与住院期间比较有所降低,但无显著性差异(P>0.05);LVEF与住院期间比较无明显升高(P>0.05)。^(131)I治疗组甲功水平、NT-Pro BNP、心室率与住院期间比较明显降低(P<0.05),LVEF与住院期间比较明显升高(P<0.05)。^(131)I组甲功水平、NT-Pro BNP、心室率较ATD治疗组明显减低(P<0.05),LVEF较ATD组明显升高(P<0.05)。结论:^(131)I治疗组能及时、有效降低老年甲亢合并心脏疾病患者的甲状腺激素水平,减慢心室率,改善心功能。Objective: To analyze the clinical efficacy of 131I and anti thyroid drugs (ATD) in the treatment of elderly patients withhyperthyroidism complicated with heart disease. Methods: Senile Hyperthyroidism Complicated with heart disease were 276 points of 131Itreatment group (146 cases) and ATD therapy group (130 cases), hospital admission were compared between two groups when age, gender, thyroidfunction level, B type natriuretic peptide (NT proBNP) precursors, heart rate, left ventricular shot ejection fraction (LVEF). The two groups wereobserved before and after treatment, the level of thyroid, plasma (NT-ProBNP), ventricular rate, LVEF and other indicators. Results: There wereno significant differences in age, gender, level of thyroid function, NT-ProBNP, ventricular rate and LVEF between the two groups (P>0.05). 3,6 and 12 months after treatment, ATD treatment group a work level, NT proBNP, ventricular rate and hospitalization period is decreased, but nosignificant difference (P>0.05). The LVEF and during hospitalization did not significantly (P>0.05). In the treatment group, the level of 131I, NTProBNP,ventricular rate and hospital stay were significantly lower (P<0.05), and LVEF was significantly higher (P<0.05) during the period ofhospitalization. The level of, NT-ProBNP and ventricular rate in group 131I was significantly lower than that in the ATD treatment group (P<0.05),and the LVEF was significantly higher than that in the ATD group (P<0.05). Conclusion: 131I treatment group can timely and effectively reducethe level of thyroid hormone in elderly patients with hyperthyroidism and heart disease, slow ventricular rate, improve heart function.

关 键 词：老年甲亢合并心脏疾病 碘131 抗甲状腺药物 甲功水平 

分 类 号：R541.85[医药卫生—心血管疾病]